| |
The porcine reproductive
and respiratory syndrome
quandary. Part I: Fact versus speculation
William L. Mengeling,
DVM, PhD, Diplomate ACVM
Department of Veterinary
Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa
State University, Ames, Iowa
Cite as: Mengeling
WL. The porcine reproductive and respiratory syndrome quandary: Fact versus
speculation. J Swine Health Prod. 2005;13(2):91-95.
This is the first part of a two-part article. The second part
will appear in the May-June 2005 issue of the Journal of Swine Health
and Production.
Despite a great deal of research on porcine reproductive and respira-
tory syndrome (PRRS) during the past 15 years, our understanding of this disease
and its causative agent, PRRS virus (PRRSV), is far from complete, and as one
of the consequences, PRRS prevention and control remains a major challenge.
Over the years, many of our efforts have focused on the development of PRRS
vaccines that we hoped would be just as effective as those used to help prevent
several other economically important viral diseases of swine (eg, swine fever,
pseudorabies, parvovirus-induced reproductive failure, and swine influenza),
but unfortunately, this has not been the case. While attenuated-live-virus
PRRS vaccines do provide clinical protection under many circumstances, and
in such cases are clearly cost effective, the level of protection is too often
less than what we have come to expect from past experiences with many other
attenuated-live-virus vaccines.
Keep in mind the shortcomings of PRRS vaccines are not due to a lack of research
effort, time, or financial commitment in regard to their development. It is
possible that at least as much time, effort, and money have been invested in
developing PRRS vaccines as in developing any other viral vaccine for pigs.
The reason for this emphasis on PRRS vaccines is not simply chance. It partly
reflects the dedication of the research community and the biologics industry
to solving a major problem. From a more pragmatic and commercial point of view,
it also reflects the enormous economic impact of PRRS ($560 to $760 million
annually in the United States alone1) and the potential
international market and financial reward for developing a highly efficacious
product.
Another piece of the PRRS puzzle that is still less than a perfect fit is
the one labeled epidemiology. We know that PRRSV can be spread from pig to
pig through direct and close contact. The question that is as yet unanswered
with certainty is just what the probabilities are for virus spreading by means
other than close contact, for example, wind currents, needles used for routine
injections, insects, and other animals. Transmission via prevailing winds seems
the most likely explanation for virus transmission among herds maintained in
high security environments. To date, aerosol transmission of PRRSV has been
experimentally confirmed for only relatively short distances,2 and
in some cases, only inconsistently.3 Unfortunately, experimental
studies typically comprise relatively few pigs. If probabilities are low, for
example, 1 in 10,000 (ie, a probability that would likely be undetected experimentally),
such spread might still be possible with large herds comprising thousands of
swine exposed daily to potentially virus-laden aerosols from an infected herd
some distance away. Of course, an important facet of the epidemiology piece
of the puzzle is the amount of PRRSV required to infect a pig. For this reason,
the topic of infectious doses, as well as various potential means of virus
transmission and how they can be interpreted in regard to epidemiology, will
subsequently be discussed in greater detail.
Several individual issues related to PRRS are addressed in the context of
what is, or is probably, a fact; is currently speculation but likely to be
true on the basis of one or more known facts; or is purely speculation without
factual basis, ie, simply an idea. Much of the emphasis will continue to be
on immunoprophylaxis and epidemiology, which are surely key issues in the quest
for PRRS prevention, control, and perhaps eventual eradication. Please keep
in mind the following. First, my experiences (ie, in regard to research studies
and field investigations) have been almost completely with North American strains
of PRRSV and the associated clinical disease. However, as more is learned about
European strains of PRRSV and the related consequences of infection, it appears
that there are more similarities to the North American situation than previously
thought.4,5 Second, what may seem to be fact (or conversely, simply
speculation) to one person may be interpreted somewhat differently by another.
Fact versus speculation
Virulent virus exposure as a means to induce immunity
Within the last couple of years, largely as a result of their disenchantment
with currently available vaccines, some producers and veterinarians in the
United States have opted to expose PRRS-naive gilts to fully virulent PRRSV
before conception. The objective is to induce a solid immunity to reproductive
failure should the gilts be exposed to virulent virus during gestation. The
strain of virulent virus chosen for "vaccination" is usually the
one most recently isolated from pigs, gilts, or sows of the same herd, and
one that is presumably the only or at least the predominant strain currently
circulating in the herd. Their rationale is their belief that fully virulent
virus will stimulate a more forceful immune response than will an attenuated
virus. If the same gilts are exposed to PRRSV during gestation, it will likely
be to the same strain with which they were vaccinated (a potential advantage
if it is assumed that strains are only partially cross-protective).
However, there are some major concerns about this approach. First, there is
always the possibility of untoward reaction following exposure of naive gilts
or sows to fully virulent PRRSV. Second, the exposure of each new group of
replacement gilts to fully virulent virus is almost surely a commitment to
continuous circulation of that strain in the breeding herd - with the potential
for its dissemination to other segments of the production cycle as well as
to neighboring herds (with attendant legal implications). Third, and of most
immediate and direct concern, is the question of whether a single exposure
to virulent virus prior to breeding really does provide a satisfactory level
of immunity.
Although the idea that exposure to a fully virulent homologous strain of PRRSV
before conception would provide a better immunity than similar exposure to
an attenuated heterologous strain is logical, the degree of difference is not
clear. To my knowledge, no one has yet confirmed, in an unbiased environment
under controlled experimental conditions, that purposely using virulent virus
stimulates sufficient immunity to consistently prevent subsequent reproductive
failure. In fact, for the few on-farm examples that have come to my attention
(ie, of using virulent virus to induce immunity followed by known exposure
to the same strain of virulent virus during gestation), the level of protection
has been less than satisfactory.6
Immunization by contact exposure during the general acclimatization of replacement
gilts
What at one time seemed to many veterinarians to be a relatively inexpensive
and promising way to induce immunity to PRRSV in replacement gilts has apparently
fallen from grace. There are a number of permutations of this procedure, but
the fundamental idea is to mix swine (eg, cull sows) that are shedding virulent
virus with naive gilts during a so-called "gilt acclimatization" interval.
The major deficiencies of this approach are, first, the difficulty in being
confident that the individuals being placed in contact with replacement gilts
are actually shedding PRRSV, and second, having PRRSV spread through the entire
group of replacement gilts well before conception. The concern about untoward
reactions following purposeful exposure of gilts to virulent PRRSV and the
introduction of virulent virus into each new "batch" of gilts applies
here just as it does following the injection of virulent virus. On the other
hand, exposure by contact is probably less of a legal concern than a more direct
means of exposure such as injection. Probably the worst-case scenario is to
have a prolonged course of infection among gilts so that some are infected
only shortly before conception and some after conception, even though the "official" acclimatization
process has been completed.
The use of inactivated (killed) vaccine to boost antibody titers
It has been stated that "The main attribute of killed PRRSV
vaccine is to boost antibody titers."7 I am unaware of any
extensive controlled experimental studies to substantiate this statement. It
is difficult to imagine how a vaccine that may fail to even raise a measurable
level of antibody in a naive pig would appreciably boost the titer in an immune
gilt or sow. What seems more likely, if inactivated vaccine is to have any
role in PRRS immunity, is its use to sensitize (prime) the immune system.6 A
possible scenario is the following. Pigs destined to become replacement gilts
would be vaccinated twice with an inactivated vaccine that would raise a measurable
level of antibody (eg, when tested by ELISA) sometime after the second vaccination.
It is possible to prepare an inactivated virus vaccine (without concentration)
that will raise a moderate level of ELISA antibody if a suitable adjuvant is
incorporated. Ideally, the vaccinal virus would be the strain circulating in
the destination herd, but there is no reason to believe this is essential.
At a much later date, but before conception, the gilts would be vaccinated
with attenuated live virus. The idea is that priming the immune system with
the homologous (or a heterologous) strain of PRRSV would enhance the magnitude
of the immune response to subsequent vaccination.
Effect of vaccination on subsequent shedding of virulent virus
It has also been stated "... nor is there a vaccine that eliminates or
even reduces virus shedding."7 Assuming that the incidence
and magnitude of virus isolation from swine of any age, sex, or breed is directly
linked with the likelihood of shedding, there is a plethora of definitive evidence
that vaccination, and more specifically preexisting immunity, markedly reduces
virus shedding.
Data from two of our experiments completed at the National Animal Disease
Center in Ames, Iowa, to determine the efficacy of vaccinating with attenuated
live virus are summarized to illustrate the effect of vaccination on reducing
the extent of infection in gilts (Table 1) and magnitude of infection in pigs
(Table 2) challenged with virulent virus. The collective incidence of virulent
PRRSV isolation (Table 1) after challenge was 14 virus-positive samples of
36 samples tested (38.9%) for nonvaccinated gilts, and three virus-positive
samples of 91 samples tested (3.3%) for vaccinated gilts. The reduction in
magnitude of PRRSV replication is evident in Table 2, in which the median cell
culture infectious doses (CCID50) of virus isolated from pigs are
presented as logarithms to the base 10 (log10). Although the log
values seem fairly close, the actual numbers are quite different. For example
(for quick reference) 102.8 = approximately 630 CCID50 per
mL of serum, whereas 100.9 = < 10 CCID50 per mL and
100.2 = approximately 1.6 CCID50 per mL. Likewise, 104.0 =
10,000 CCID50 per mL of lavage fluid, whereas 101.5 =
approximately 32 CCID50 per mL and 101.4 = approximately
25 CCID50 per mL. It appears that vaccination can result in more
than a 300-fold reduction (10,000 32) in the magnitude of virulent virus in
the lung of a vaccinated pig. If we extrapolate this finding to the likelihood
of virus shedding, it is entirely possible that the likelihood of shedding
is also reduced by more than 300-fold (or generally somewhat less if the comparison
is made on the basis of viremia), a substantial difference.
The practical importance of infectious dose in regard to epidemiology
Previous studies have indicated the amounts of PRRSV required to infect pigs
by either injection or intranasal exposure,8 and to infect gilts
by artificial insemination.9 In both cases, the infectious dose
is actually a comparative value. That is, in both studies, the titer of PRRSV
was first determined in cell culture, then the pig or gilt infectious dose
was reported on the basis of how many infectious virions or CCID50 were
required for infection. Otherwise, an infectious dose by definition would simply
be one. It was found that pigs were infected by either injection or intranasal
exposure with 20 infectious virions. Lesser amounts were not tested.8 Gilts
exposed by artificial insemination were infected consistently with either 2
x 105 or 2 x 106 CCID50, infrequently with
20,000 or 2000 CCID50, but not at all with 200 CCID50.9 Of
course, the means by which the infectious dose was determined is always indicated
in a scientific manuscript, but an infectious dose for the natural host is
likely to be a comparative value (with the additional associated variables)
rather than a direct measurement, ie, actually a titration in the natural host.
It is too expensive to routinely make titrations in a natural host; therefore,
an alternate host, commonly cell culture, is used. For example, for a series
of 10 progressive 10-fold dilutions with 10 replications (to provide statistical
confidence) for each dilution, 80 gilts and 80 individual isolation facilities
would be required. The cost of such a titration method would be prohibitive
for most laboratories. However, there are disadvantages to using an alternate
host to determine infectious virions or CCID50, and then making
statements concerning the number of CCID50 it took to infect a pig
by the given route of exposure. Propagating the virus in the alternate host
for several passages can change the result. For example, by testing a virus
that has been passaged infrequently in cell culture, it may be determined that
pigs can be infected with 20 or fewer infectious virions.8 However,
we have found that after repeated passage of PRRSV in cell culture (251 passages
to be exact), some pigs are not infected even when exposed to 2 x 106 CCID50.10 The
use of the term "infectious virions" in some cases and "CCID50" in
others reflects the particular method of virus titration used in the experiment
from which the data was extrapolated. To compare these values, consider that
1 CCID50 = 0.7 of an infectious virion - assuming both values were
determined in the same type of cell culture. What we can glean from this discrepancy
is that when an alternate host is used to determine infectious virions or CCID50,
which are in turn used to suggest how little or how much virus is required
to consistently infect the natural host, the titration should be done before
that particular virus is adapted to the alternate host - and more importantly,
away from the natural host. Otherwise, we may be influenced by factual but
misleading information. The loss of infectivity for pigs by repeated passage
of PRRSV in cell culture should be taken into account when one is tempted to
dilute a live-virus vaccine.
With all of these reservations, one may question the value of determining
an infectious dose. But the fact is that it is an important bit of information
in sorting out the epidemiology of PRRS. When we know that pigs can consistently
be infected with 20 or fewer infectious virions of PRRSV, we immediately
know that PRRSV is highly infectious, at least for young pigs. As the lowest
dose to which pigs were exposed was 20 infectious virions, and all of the pigs
thus exposed were infected, we don't know whether an even lower dose would
have been sufficient to consistently infect pigs. In addition, it is logical
to assume that it really takes only one of the infectious virions to infect
a pig. That is, if the statement were more precise, eg, 20 infectious virions
(determined with cell culture) instead of <= 20 infectious virions to infect
a pig, and we set aside statistical variability, we can assume that we would
infect one pig whether we gave the whole dose to a single pig or divided the
dose into 20 equal aliquots and gave one aliquot to each of 20 pigs. So if
the probability of infection is 1:20, in contrast to actually requiring the
simultaneous administration of 20 infectious virions to infect a pig, it becomes
easier to speculate about how a virus such as PRRSV could spread to large herds
by aerosol, even if prevailing winds carry very little virus per unit volume.
The problem is actually proving the role of aerosols, assuming that they really
are important.
The same probability reasoning can be applied to the likelihood of infecting
gilts through semen. First, we can assume that semen contaminated with PRRSV
probably contains a small amount of the virus. Such an assumption is supported
by the fact that if we dilute semen, even as little as 100-fold, for the purpose
of reducing its cytotoxicity for cell cultures, we often fail to detect virus
contamination that can be detected by another technique, namely, by the polymerase
chain reaction (PCR). If this were not the case, we might routinely test semen
by virus isolation to address the concern that a positive PCR does not confirm
the presence of infectious virus. So if it requires 2000 or more CCID50 to
infect a gilt via insemination, and semen probably rarely, if ever, contains
that amount of virus, how can semen serve as an important vehicle for virus
transmission? The cytotoxicity problem precludes a thorough evaluation of the
amount of infectious virus present in semen of an infected boar. We can speculate,
with a high degree of confidence, that probability is the answer. That is,
if, for example, it requires 2000 CCID50 in semen to infect gilts,
then insemination with 200 CCID50 will result in infection of one
of every 10 inseminated gilts, insemination with 20 CCID50 will
result in infection of one of every 100 inseminated gilts, and so forth. Again,
the above ignores statistical variation as it would affect these comments.
What are some of the practical implications of the above? First, although
it may require 2000 CCID50 to routinely infect a gilt in this example,
the possibility that a single CCID50 will infect a gilt is not excluded
- and it will surely happen if enough gilts are exposed. Second, the understanding
of this probability issue helps us understand why it is so difficult to keep
PRRSV out of large herds. If we assume the probability of infection through
semen is 1:2000, then a swine producer who inseminates 20 gilts per year would,
on average, introduce PRRSV into his or her herd once every 100 years, whereas
a swine producer who inseminates 2000 gilts per year would, on average, introduce
PRRSV into his or her herd every year. Of course, this illustration assumes
that semen always comes from infected boars, and there is statistical variability,
so the previous statement is not entirely correct from a mathematical standpoint.
But it nevertheless emphasizes the formidable challenges associated with virus
spread to and within large herds, and the additional complexities of disease
prevention and control in today's swine production systems.
Transmission of PRRSV via needles
A final topic that will be considered is the probability of transferring PRRSV
during routine injections.11 Before discussing the real-world situation,
I will point out that under experimental conditions, we always changed needles
as well as syringes between injections of pigs, gilts, or sows, because even
if the chance of transmission was only 1 in 10,000, we wanted to evaluate experimental
results with as few variables as possible. There is little disincentive for
spending a few extra dollars for additional needles and syringes or spending
a few extra hours during an experiment that may cost tens of thousands of dollars
and last for at least several months. But under farm conditions, I think of
procedures in terms of whether they are cost effective, and that is
the approach I take in the following. Because the likelihood of transmission
of PRRSV by a hypodermic needle is much greater in young pigs than in gilts
and sows, we will look at them separately.
First, we will assume that the titer of infectious PRRSV is the same in intracellular
and intercellular fluids (ie, relative to cells and intercellular spaces penetrated
with a needle at the injection site) as it is in blood. It may be much less,
on the basis of a previous study12 wherein PRRSV was isolated from
only one of 28 samples of muscle collected from seven viremic pigs (four samples
per pig from various sites). We will make the assumption anyway, so that any
error is on the positive side (likelihood of transmission). If, for example,
the titer were about 106 CCID50 per mL of blood (maximum
expected) and by our assumption the same in the intercellular and intracellular
fluids, and 5 mL of fluid adhered to the outside of the needle as it was withdrawn
from the injection site, the needle would be contaminated with 5000 CCID50.
Because pigs can be infected with 20 or fewer infectious virions (and as few
as one), we can logically assume that PRRSV could be transferred from pig to
pig via a contaminated needle even though the virus titer in the blood of an
infected pig is more likely much less than 106. For example, in
the study represented in Table 2, the average titer of PRRSV in the blood of
nonvaccinated pigs 7 days after challenge with virulent virus was 102.8 CCID50.
But whatever the virus titer in blood and tissues, and despite other potential
variables, we are left with the idea that contaminated needles could play an
important role in the transmission of PRRSV among young pigs. Of course, if
the infected and naive pigs are in direct contact anyway, eg, littermates or
simply housed in the same pen, the question is whether it makes any difference
if they are exposed through the use of contaminated needles or by contact.
More emphasis has been placed on the potential role of contaminated needles
in the transmission of PRRSV among pregnant gilts and sows wherein infection
may result in reproductive failure. Fortunately, the titer of PRRSV in the
blood and tissues of an adult is appreciably less than in a young pig, and
the threshold of infection is probably higher, so we can speculate that the
risk is much less. If we make most of the same assumptions made in the example
for pigs, except that the titer of virus in blood and tissues is much less,
eg, 102 CCID50, the amount of virus contaminating the
needle as it is withdrawn from the injection site would be 0.5 CCID50.
If, in addition, the threshold of infection is higher for gilts and sows than
it is for younger pigs, it seems that transmission by a contaminated needle
from one gilt or sow to another gilt or sow is a very unlikely event. Moreover,
if the gilts or sows are in the same pen or in adjacent gestation stalls and
perhaps drinking from a common water trough, does the potential for transmission
by needle even approach that of other potential modes of transmission? As a
compromise between expense (time and money) and risk, needles are sometimes
changed after every 3rd injection (ie, for every 3rd gilt
or sow). This procedure would likely reduce the risk of transmission only 33%,
since only the 1st injection in each set of three would be with
a new needle. Perhaps the rationale is that changing after every 3rd injection
would prevent a whole series of exposures if the same needle were used over
and over again. But serial transmission seems unlikely in view of the small
amount of contamination and the likelihood that the needle would be more or
less "wiped clean" as it was injected into and then withdrawn from
the next injection site.
Clearly, some of what has been presented here in regard to PRRSV transmission
by contaminated needles is speculative. Any experiment to definitively determine
probabilities, especially in regard to transmission among gilts and sows, might
be prohibitively expensive, but there is one relatively inexpensive experimental
approach that would shed some light on the issue. Needles withdrawn from injection
sites in PRRSV infected pigs, or gilts, or sows would simply be rinsed in a
small volume of cell culture medium, which in turn would be tested in cell
culture for infectious virus. By this procedure, it might be possible to determine
if needle contamination is a common or rare event, and the relationship between
the titer of PRRSV detected in the blood (and, by inference, in tissues) and
the likelihood of contamination. If, for example, contamination was rarely,
if ever, detected when needles were withdrawn from injection sites despite
even high titers of circulating virus, we would probably be less concerned
about this mode of transmission.
Some final comments
An attempt was made in the previous sections to address what is known, or
at least speculated, about some issues related to prevention and control of
PRRS. Unfortunately, the disease continues to have a major economic impact
on the swine industry worldwide. What can be done to further reduce its negative
effect on pork production is not entirely clear. Recently, there was a substantial
increase in both government and industry funding for PRRS research in the United
States. The hope is that this additional emphasis will do more than just add
incrementally to our current knowledge. At this point, it appears that better
control of this virus and better prevention of the respiratory and reproductive
syndromes with which it is associated will require new and innovative ideas,
or, at the very least, some repackaging of our current strategies, which are
largely patterned after successful approaches to the prevention and control
of several other diseases of swine.
Acknowledgement
Material presented in this review has been previously published in Polish,13 Spanish,14 or
both, and some data were adapted from Mengeling et al 2003.15
References
*1. Johnson C, Kliebenstein J, Mabry J, Neumann E. The impact of PRRS on the
cost of pig production. Proc Allen D. Leman Swine Conf.
2004 (suppl):11.
2. Kristensen CS, Botner A, Takai H, Nielsen JP, Jorsal SE. Experimental airborne
transmission of PRRS virus. Vet Microbiol. 2004;99:197-202.
3. Wills RW, Zimmerman JJ, Yoon K-J, Hill HT, Bundy DS, McGinley MJ. Transmission
of PRRSV by direct close or indirect contact. Swine Health Prod.
1997;5:213-218.
4. Forsberg R, Storgaard T, Nielsen HS, Oleksiewicz MB, Cordioli P, Sala G,
Hein J, Botner A. The genetic diversity of European type PRRSV is similar to
that of the North American type but is geographically skewed within Europe. Virology.
2002;299:38-47.
*5. Martelli P. Do recent epizootics of European PRRS indicate the emergence
of more virulent strains of the causative virus? Proc SEPOR. 2004:21-40.
*6. Mengeling WL. PRRS vaccinology: Past, present, future. Proc AASV.
Toronto, Canada. 2005. In press.
*7. Hill HT, Mulford JA, Kaisand JJ, Holtcamp A, Reyes C. PRRS control: To
hell and back. Proc AASV.
Des Moines, Iowa. 2004:369-375.
8. Yoon KJ, Zimmerman JJ, Chang CC, Cancel-Tirado S, Harmon KM, McGinley MJ.
Effect of challenge dose and route on porcine reproductive and respiratory
syndrome virus (PRRSV) infection in young swine. Vet Res. 1999;30:629-638.
*9. Benfield DA, Nelson E, Steffen M, Rowland R. Transmission of PRRSV by
artificial insemination using extended semen seeded with different concentrations
of PRRSV. Proc AASP. Indianapolis, Indiana. 2000:405-408.
10. Mengeling WL, Lager KM, Vorwald AC, Koehler KJ. Strain specificity of
the immune response of pigs following vaccination with various strains of porcine
reproductive and respiratory syndrome virus. Vet Microbiol. 2003;93:13-24.
11. Otake S, Dee SA, Rossow KD. Transmission of porcine reproductive and respiratory
syndrome virus by needles. Vet Rec. 2002;150:114-115.
12. Mengeling WL, Lager KM, Vorwald AC. Diagnosis of porcine reproductive
and respiratory syndrome. J Vet Diagn Invest. 1995;7:3-16.
*13. Mengeling WL. The porcine reproductive and respiratory syndrome (PRRS)
quandary: Fact versus speculation. Proc Kongress Polskiego Towarzystwa Nauk
Weterynaryjnych. Warszawa, Poland. 2004:306-309.
*14. Mengeling WL. The porcine reproductive and respiratory syndrome (PRRS)
quandary: Fact versus speculation. Proc SEPOR. 2004:7-19.
15. Mengeling WL, Lager KM, Vorwald AC, Clouser DF. Comparative safety and
efficacy of attenuated single-strain and multi-strain vaccines for porcine
reproductive and respiratory syndrome. Vet Microbiol. 2003;93:25-38.
* Non-refereed references.
|
|